| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0003993 | Acid phosphatase activity | Decreases phenotype | PMID:28421826 |
| GO:0004035 | Alkaline phosphatase activity | Decreases phenotype | PMID:28421826 |
| GO:0004364 | Glutathione transferase activity | Decreases phenotype | PMID:28373059; PMID:31004597 |
| GO:0004602 | Glutathione peroxidase activity | Affects phenotype | PMID:28373059; PMID:28421826; PMID:33347680 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:28373059; PMID:28421826; PMID:28988496; PMID:31004597; PMID:33347680 |
| GO:0006606 | Protein import into nucleus | Affects phenotype | PMID:33347680 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:28421826; PMID:28904557; PMID:28988496; PMID:33347680 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:28373059; PMID:31004597 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:28373059; PMID:31004597 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:25034532; PMID:27451028; PMID:37121058 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:28988496 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:28421826 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:25034532; PMID:27451028 |
| GO:0008284 | Positive regulation of cell population proliferation | Decreases phenotype | PMID:28249781 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:29555536 |
| GO:0010884 | Positive regulation of lipid storage | Decreases phenotype | PMID:26498061 |
| GO:0014068 | Positive regulation of phosphatidylinositol 3-kinase signaling | Decreases phenotype | PMID:28249781 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:28373059; PMID:28421826; PMID:28988496; PMID:33347680 |
| GO:0016477 | Cell migration | Affects phenotype | PMID:32926756 |
| GO:0019852 | L-ascorbic acid metabolic process | Affects phenotype | PMID:33347680 |
| GO:0030027 | Lamellipodium | Decreases phenotype | PMID:32926756 |
| GO:0032148 | Activation of protein kinase b activity | Decreases phenotype | PMID:28249781 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:28904557; PMID:31004597 |
| GO:0042360 | Vitamin e metabolic process | Affects phenotype | PMID:33347680 |
| GO:0042743 | Hydrogen peroxide metabolic process | Affects phenotype | PMID:28421826 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:28249781 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:36341865; PMID:37121058 |
| GO:0044319 | Wound healing, spreading of cells | Decreases phenotype | PMID:32926756 |
| GO:0045600 | Positive regulation of fat cell differentiation | Decreases phenotype | PMID:26498061 |
| GO:0046209 | Nitric oxide metabolic process | Affects phenotype | PMID:28421826 |
| GO:0050665 | Hydrogen peroxide biosynthetic process | Increases phenotype | PMID:28373059 |
| GO:0051726 | Regulation of cell cycle | Increases phenotype | PMID:28249781 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:27451028; PMID:28988496 |
| GO:0060740 | Prostate gland epithelium morphogenesis | Decreases phenotype | PMID:28904557 |
| GO:0061370 | Testosterone biosynthetic process | Affects phenotype | PMID:28421826 |
| GO:0071902 | Positive regulation of protein serine/threonine kinase activity | Increases phenotype | PMID:28249781 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:25034532; PMID:28988496 |
| GO:0090200 | Positive regulation of release of cytochrome c from mitochondria | Increases phenotype | PMID:28249781 |
| GO:0090263 | Positive regulation of canonical wnt signaling pathway | Increases phenotype | PMID:26498061 |
| GO:0097722 | Sperm motility | Decreases phenotype | PMID:28421826 |
| GO:1900744 | Regulation of p38mapk cascade | Affects phenotype | PMID:28249781 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:27451028 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.